CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
达沙替尼用于治疗 CAR-T 细胞治疗相关并发症
英文原题：Dasatinib for treatment of CAR T-cell therapy-related complications.
查看英文原题
Dasatinib for treatment of CAR T-cell therapy-related complications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）是CAR-T 细胞治疗的严重且可能危及生命的不良反应，由增殖和活化的CAR-T 细胞释放细胞因子所致。目前主要治疗包括阻断白细胞介素-1和白细胞介素-6（IL-6）及使用类固醇。类固醇的使用仍有争议，因为其可能不可逆地损害CAR-T 细胞，从而增加复发风险。因此，需要探索其他治疗方案。我们报告一例3级CRS和4级ICANS患者，对IL-6阻断和类固醇治疗无效，使用酪氨酸激酶抑制剂达沙替尼后成功治疗。达沙替尼用于治疗CAR-T 相关严重并发症，仍需进一步研究。
展开英文摘要原文
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse.
Therefore, additional treatment options need to be explored.
We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies.
论文信息
- 作者
- Baur K、Heim D、Beerlage A、Poerings AS、Kopp B、Medinger M、Dirks JC、Passweg JR
- 单位
- Division of Hematology, University Hospital, Basel, Switzerland katharina.baur@usb.ch.Switzerland
- 期刊
- Journal for immunotherapy of cancer2022 Dec
- 原文标识
- PubMed 36455991 · DOI 10.1136/jitc-2022-005956
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →